Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00191412 |
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
Condition | Intervention | Phase |
---|---|---|
Liver Cancer |
Drug: Pemetrexed |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of Single-Agent Alimta in the Treatment of Patients With Advanced and Metastatic Hepatoma |
Estimated Enrollment: | 41 |
Study Start Date: | January 2005 |
Study Completion Date: | March 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Colorado | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician | |
Denver, Colorado, United States |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT) - 5 hours, EST) | Eli Lilly and Company |
Study ID Numbers: | 9417, H3E-US-S055 |
Study First Received: | September 12, 2005 |
Last Updated: | November 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00191412 |
Health Authority: | United States: Food and Drug Administration |
Folic Acid Pemetrexed Liver Neoplasms Liver Diseases Digestive System Diseases |
Digestive System Neoplasms Liver neoplasms Neoplasm Metastasis Gastrointestinal Neoplasms Hepatocellular carcinoma |
Antimetabolites Neoplasms Antimetabolites, Antineoplastic Neoplasms by Site Molecular Mechanisms of Pharmacological Action |
Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Folic Acid Antagonists Pharmacologic Actions |